Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01333878 · ClinicalTrials.gov registry record · Phase 2
Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage
A Phase 2 study of Rheumatoid Arthritis, sponsored by Orrin M Troum, M.D. and Medical Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT01333878 is a Phase 2 study of Rheumatoid Arthritis that has completed, run by Orrin M Troum, M.D. and Medical Associates. The registered enrollment target is 12 participants, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01333878, a Phase 2 study of Rheumatoid Arthritis, has completed, sponsored by Orrin M Troum, M.D. and Medical Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this study is that subcutaneous Abatacept is effective in reducing synovial inflammation, osteitis, and erosions in Rheumatoid Arthritis as assessed by low field extremity MRI and X-ray.
Conditions Studied
Interventions
- BIOLOGICAL Subcutaneous Abatacept
Study Locations (1)
California
- Orrin M. Troum, MD and Medical Associates - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01333878
The ClinicalTrials.gov registry entry for NCT01333878 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,691-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (100% lower). The listed sponsor is Orrin M Troum, M.D. and Medical Associates, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 1 intervention - of which Subcutaneous Abatacept is the first listed.
NCT01333878 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT01333878 about?
NCT01333878 is a clinical study titled "Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage". The hypothesis of this study is that subcutaneous Abatacept is effective in reducing synovial inflammation, osteitis, and erosions in Rheumatoid Arthritis as assessed by low field extremity MRI and X-ray.
What is the current status of trial NCT01333878?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2011-03. Estimated completion is 2014-01.
What conditions does trial NCT01333878 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT01333878?
The interventions under investigation include: Subcutaneous Abatacept (BIOLOGICAL).
Who is sponsoring clinical trial NCT01333878?
This trial is sponsored by Orrin M Troum, M.D. and Medical Associates, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01333878 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of SPY072 in Rheumatic Disease
RECRUITING · Phase 2
-
Dynamic Treatment Regiments for Glucocorticoid Tapering
RECRUITING · Phase 2
-
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
RECRUITING · Phase 2
-
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.